For its fourth fiscal quarter (ending December 31), Zimmer Biomet Holdings Inc (NYSE: ZBH) has reported a -41% decline in E.P.S. from $2.02 a year ago to $1.20 in the current quarter. For the latest four quarters through December 31, E.P.S. were $4.45 compared to $4.91 a year ago — a decline of -9%.
Recent Price Action
On 2/6/25, Zimmer Biomet Holdings Inc (NYSE: ZBH) stock suffered a large decline of -5.1%, closing at $102.69. Moreover, this decline was accompanied by exceptionally high trading volume at 232% of normal. Relative to the market the stock has been weak over the last nine months and has declined -7.5% during the last week.
Current PriceTarget Research Rating
Zimmer Biomet Holdings has a current Value Trend Rating of D (Negative). This rating combines highly consistent signals from two proprietary PTR measures of a stock’s attractiveness. Zimmer Biomet Holdings has a neutral Appreciation Score of 48 and a neutral Power Rating of 42, producing the Negative Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment